Prostate Cell News Volume 5.24 | Jul 4 2014

Hepatocyte Growth Factor-Like Protein Is Required for Prostate Tumor Growth in the TRAMP Mouse Model
Scientists examined host-produced hepatocyte growth factor-like protein in tumorigenesis in prostate cancer by using the TRAMP mouse model, which is predisposed to develop prostate tumors. [Oncotarget] Full Article

Guggulsterone Inhibits Prostate Cancer Growth via Inactivation of Akt Regulated by ATP Citrate Lyase Signaling
Investigators reveal a novel mechanism of Guggulsterone (Gug)-anticancer activity that ATP citrate lyase-regulated Akt inactivation is involved in Gug-mediated inhibition of prostate cancer growth. [Oncotarget]
Full Article

TR4 Nuclear Receptor Promotes Prostate Cancer Metastasis via Up-Regulation of CCL2/CCR2 Signaling
Through in vitro migration/invasion assays after manipulation of the testicular nuclear receptor 4 (TR4) expression in prostate cancer (PCa) cells, researchers demonstrate that TR4 promoted PCa cells migration/invasion. [Int J Cancer] Abstract

Elevated YKL40 Is Associated with Advanced Prostate Cancer
YKL40 is a secreted glycoprotein highly expressed in tumors from patients with advanced stage cancers, including prostate cancer (PCa). Scientists examined the expression and function of YKL40 in PCa.
[Endocr Relat Cancer] Abstract

A Genome-Wide RNAi Screen Identifies FOXO4 as a Metastasis-Suppressor through Counteracting PI3K/AKT Signal Pathway in Prostate Cancer
Activation of the PI3K/AKT signal pathway is a known driving force for the progression to castration-recurrent prostate cancer (CaP). Researchers investigated FOXO4, the PI3K/AKT-inactivating downstream target, as a potential CaP metastasis suppressor. [PLoS One] Full Article

miR-26a Inhibits Prostate Cancer Progression by Repression of Wnt5a
Researchers investigated the role of miR-26a and report that miR-26a expression was lower in prostate cancer tissues compared with their normal controls and Wnt5a is a potential target gene of miR-26a. [Tumour Biol] Abstract

Cisplatin Modulates B-Cell Translocation Gene 2 to Attenuate Cell Proliferation of Prostate Carcinoma Cells in Both p53-Dependent and p53-Independent Pathways
Scientists evaluated the cisplatin effects on prostate cancer cell proliferation and the expressions of B-cell translocation gene 2, p53, androgen receptor and prostate specific antigen in prostate carcinoma. [Sci Rep]
Full Article

CLINICAL RESEARCH

Activity and Safety of ODM-201 in Patients with Progressive Metastatic Castration-Resistant Prostate Cancer (ARADES): An Open-Label Phase I Dose-Escalation and Randomized Phase II Dose Expansion Trial.
ODM-201 is a novel androgen receptor (AR) inhibitor designed to block the growth of prostate cancer cells through high-affinity binding to the AR and inhibition of AR nuclear translocation. Researchers assessed ODM-201’s safety, pharmacokinetics, and activity in men with metastatic castration-resistant prostate cancer.
[Lancet Oncol] Abstract

Non-Steroidal Antiandrogen Monotherapy Compared with Luteinizing Hormone-Releasing Hormone Agonists or Surgical Castration Monotherapy for Advanced Prostate Cancer
Investigators assessed the effects of non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for treating advanced stages of prostate cancer. [Cochrane Database Syst Rev] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

BIDMC Cancer Center Launches Institute for RNA Medicine
The Cancer Center at Beth Israel Deaconess Medical Center (BIDMC) has launched a new research institute to harness the potential of RNA to revolutionize the way cancer and ultimately other diseases are treated and diagnosed. [Beth Israel Deaconess Medical Center] Press Release

From our sponsor: Pluripotent cell isolation for regenerative medicine. Request a free wallchart from Nature.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the prostate cell community.

Postdoctoral Fellow – Translational Prostate Cancer (Cleveland Clinic)

Postdoctoral Fellow – Prostate Cancer Research (Tulane University Health Sciences Center)

Postdoctoral Scientist – Prostate Oncobiology (Cancer Research UK Manchester Institute)

Postdoctoral Position – Role of Chromatin in Prostate Cancer (University of Victoria)

Postdoctoral Fellow – Prostate Cancer Research (Henry Ford Hospital)

Research Fellow – Molecular Mechanisms of Prostate Cancer (Northwestern University- Feinberg School of Medicine)

Postdoctoral Research Associate – Prostate Cancer Research (Medical University of South Carolina)

Scientist – Prostate Cell Research (STEMCELL Technologies Inc.)

Scientist – Pluripotent Stem Cell Media Development: High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.